AMX0035—approved as Relyvrio in 2022 for amyotrophic lateral sclerosis but voluntarily pulled from the market last year— was unable to distinguish itself from placebo in a mid-to-late-stage trial of progressive supranuclear palsy.
AMX0035—approved as Relyvrio in 2022 for amyotrophic lateral sclerosis but voluntarily pulled from the market last year— was unable to distinguish itself from placebo in a mid-to-late-stage trial of progressive supranuclear palsy.